Table 1.
Patient Characteristics
| Clinicopathologic features | n = 237 (%) |
|---|---|
| Male | 64 (27) |
| Female | 173 (73) |
| Age at diagnosis (years), mean ± SD | 48 ± 15 |
| Tumor size (cm), mean ± SD | 2 ± 1.2 |
| Lymph node metastasis | |
| Central | 101 (43) |
| Total number of CLN dissected | 7.9 ± 6.0 |
| Positive number of CLN dissecteda | 3.9 ± 3.3 |
| Extrathyroidal extension | 55 (23) |
| Multifocality | 95 (40) |
| Lymphovascular invasion | 30 (13) |
| Involvement of surgical margins | 34 (14) |
| AJCC | |
| Stage I | 147 (62) |
| Stage II | 10 (4) |
| Stage III | 77 (33) |
| Stage IV | 3 (1) |
| Subtype | |
| Classical | 192 (81) |
| Follicular | 27 (11) |
| Tall cell | 18 (8) |
| BRAF mutation positive, n (%) | 170 (72) |
| Classical | 149 (78) |
| Follicular | 6 (22) |
| Tall cell | 15 (83) |
| microRNAs,b mean (SD) | |
| 21 | −0.50 (1.97) |
| 146b-3p | −7.75 (1.97) |
| 146b-5p | −0.12 (1.71) |
| 204 | −7.91 (1.80) |
| 221 | −2.27 (1.78) |
| 222 | 0.09 (1.35) |
| 375 | −6.30 (2.21) |
a
Only includes those patients with positive disease.
b
Inverse dCt values relative to miR-16.
AJCC, American Joint Committee on Cancer; CLN, central lymph node; SD, standard deviation.